Abstract
Prior research has identified differences between sexes in rheumatoid arthritis (RA) disease characteristics and treatment response, but not how these differences affect therapeutic decision making to switch therapy. Our objective was to assess for sex differences in RA disease activity during the course of biologic therapy and how these differences impact drug survival and therapeutic switching. Data from the Alberta Biologics Pharmacosurveillance Program, a population-based observational cohort of patients receiving biologic therapy for RA, were used for a sex-stratified analysis of disease activity. Linear mixed-model analysis was applied to compare continuous effectiveness outcomes (DAS28, HAQ scores, visual analogue scales of patient-reported outcomes). Chi-squared tests and log-rank tests were used to determine differences in the frequency of switching and drug survival between females and males. At biologic initiation, females (n = 419) and males (n = 148) had similar disease activity (DAS28 in females 5.83, males 5.72), but females reported worse function (HAQ 1.64 vs 1.51, p = 0.037) and more fatigue (6.7 vs 5.9/10, p = 0.013), but the same global score as males (6.9 vs 6.8/10). During biologic therapy, females reported more fatigue (β = −0.454, 95 % CI −0.852, −0.056, p = 0.0252), worse function (β = −0.183, 95 % CI −0.291, −0.074, p = 0.0010) and higher DAS28 scores (β = −0.401, 95 % CI −0.617, −0.184, p = 0.0003). A new composite disease activity index, the HUPI, eliminated the observed differences in disease activity scores between females and males. Median survival for biologic-naïve patients was similar between sexes (3.7 years males, 3.3 years females, log-rank test p = 0.25). The frequency of switching and survival on subsequent biologics were the same between females and males. Guided by traditional outcome measurement tools, worse disease activity and patient-reported outcomes through the course of therapy did not translate into differences in drug survival or more frequent switching for females on biologic therapy for RA.
References
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62(6):1576–1582. doi:10.1002/art.27425
Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37(12):2475–2485. doi:10.3899/jrheum.091432
Jawaheer D, Olsen J, Hetland ML (2012) Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis: results from the DANBIO registry. J Rheumatol 39(1):46–53. doi:10.3899/jrheum.110548
Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66(1):46–52. doi:10.1136/ard.2006.056937
Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British society for rheumatology biologics register. Rheumatol (Oxf) 45(12):1558–1565. doi:10.1093/rheumatology/kel149
Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE (2012) Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 64(12):1811–1818. doi:10.1002/acr.21762
Barr SG, Martin L, Chung C, Maksymowych WP (2004) Mandatory pharmacosurveillance: a Canadian model for access to therapy and research. Clin Exp Rheumatol 22(5 Suppl 35):S39–S43
Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, Maksymowych WP (2012) Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-201918
Castrejon I, Carmona L, Ortiz AM, Belmonte MA, Martinez-Lopez JA, Gonzalez-Alvaro I (2013) Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis. Arthritis Care Res (Hoboken) 65(4):518–525. doi:10.1002/acr.21854
Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF (2012) Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 10:82. doi:10.1186/1741-7015-10-82
Arkema EV, Neovius M, Joelsson JK, Simard JF, van Vollenhoven RF (2012) Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Ann Rheum Dis 71(7):1203–1206. doi:10.1136/annrheumdis-2011-200947
Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Geher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11(1):R7. doi:10.1186/ar2591
Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B (2007) Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol 34(12):2382–2387
Ahlmen M, Svensson B, Albertsson K, Forslind K, Hafstrom I, Group BS (2010) Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis 69(1):230–233. doi:10.1136/ard.2008.102244
Conflict of interest
The authors declare that they have no conflict interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J., Mason, R., Martin, L. et al. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int 34, 1449–1453 (2014). https://doi.org/10.1007/s00296-014-2999-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-2999-x